Showing results (371-380 of 407) with videos related to

Sort By:
Pageof 41
Annals of the Rheumatic Diseases|December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
The Journal of Rheumatology|September 3, 2019
Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RAWalter P Maksymowych, Oliver FitzGerald, Mikkel Østergaard, et al.
Annals of the Rheumatic Diseases|February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|January 1, 2022
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registryPedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, et al.
Annals of the Rheumatic Diseases|December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
The Journal of Rheumatology|September 17, 2019
Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM CohortAlexandre Sepriano, Sofia Ramiro, Oliver FitzGerald, et al.
Annals of the Rheumatic Diseases|February 19, 2014
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trialFrank Behrens, Paul P Tak, Mikkel Østergaard, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
Pageof 41